DermaScan key facts
as of Oct 2026- Provider of skin cancer screening services designed to detect and manage skin cancer risk.
- DermaScan is valued at approximately $950K as of Oct 2026 (last reported valuation).
- It has raised $2.8M; the latest was Early Stage VC ($2.5M) in Feb 2026.
- Notable investors include Kima Ventures, Techmind, Ring Capital, Celine Lazorthes, 199 Ventures — 7 tracked in total.
- Status: Privately Held (backing).
DermaScan's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·Watch DermaScan: the Monday email on marks, rounds and moves
DermaScan funding rounds
No funding rounds for DermaScan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
DermaScan valuation
DermaScan's last reported valuation was $950,000 in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
DermaScan investors
7 investors are on record for DermaScan, including Kima Ventures, Techmind, Ring Capital and Celine Lazorthes.
About DermaScan
Provider of skin cancer screening services designed to detect and manage skin cancer risk. The facility offers body mapping, analysis of suspicious lesions, diagnosis, and follow-up plans, with referrals to dermatologists as needed, consultations utilizing advanced technology for skin cancer detection, enabling patients to diagnose skin cancer at an early stage.
- Sector
- Healthcare
- HQ
- Paris, France
- Employees
- 9
- Website
- dermascan.fr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.